MedPath

Efficacy of Melatonin in Burning Mouth Syndrome (BMS)

Not Applicable
Completed
Conditions
Burning Mouth Syndrome
Interventions
Dietary Supplement: melatonin
Registration Number
NCT02580734
Lead Sponsor
University of Milan
Brief Summary

The purpose of this study is to determine whether melatonin is effective in the treatment of burning mouth syndrome (BMS).

Detailed Description

This is a crossover trial involving a total of 20 patients with Burning Mouth Syndrome, considered a chronic neuropathic pain. In two consecutive treatment periods, both 8 week long, each patient receives externally indistinguishable capsules (placebo or melatonin). A 4 weeks wash-out period is applied, between these two periods.

The capsules contain either placebo or 3 mg-melatonin (4 time/day for a total of 12 mg/day of melatonin). The primary endpoint is the change in pain intensity at the end of each treatment period, measured using VAS, verbal intensity score and NRS, as well as number of oral sites affected by the burning sensation. Furthermore, data from quality of life, anxiety and sleep questionnaires are collected (sf-36, HAM-A, ESS, MOS).

Adverse effects are carefully recorded as well as blood samples, in order to measure serum melatonin levels during the trial.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • patients over 18 yrs suffering from burning mouth syndrome
Exclusion Criteria
  • epilepsy
  • pregnancy
  • concomitant treatment with melatonin
  • concomitant anticoagulants
  • night time working persons

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
placebomelatonintablet without melatonin
melatoninmelatonintablet with melatonin
Primary Outcome Measures
NameTimeMethod
Reduction/resolution of symptoms in BMSwithin the first 60 days
Secondary Outcome Measures
NameTimeMethod
improvement in quality of lifewithin the first 60 days
© Copyright 2025. All Rights Reserved by MedPath